CTA
AVIR icon

Colonial Trust Advisors’s Atea Pharmaceuticals AVIR Stock Holding History

Colonial Trust Advisors’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-46
Closed -$152 – 749
2024
Q2 		$152 Hold
46
– – ﹤0.01% 739
2024
Q1 		$186 Hold
46
– – ﹤0.01% 988
2023
Q4 		$140 Hold
46
– – ﹤0.01% 887
2023
Q3 		$138 Hold
46
– – ﹤0.01% 894
2023
Q2 		$172 Hold
46
– – ﹤0.01% 880
2023
Q1 		$154 Hold
46
– – ﹤0.01% 875
2022
Q4 		$221 Buy
+46
New +$233 ﹤0.01% 865

Other funds holding AVIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Colonial Trust Advisors's AVIR Position: Q3 2024 in Review

Colonial Trust Advisors sold out of Atea Pharmaceuticals (AVIR) in Q3 2024, closing a stake of 46 shares — an estimated $152 sold.

Colonial Trust Advisors first reported a position in AVIR in Q4 2022 and held it in 7 quarters. The position peaked at $221 in Q4 2022. 108 funds tracked by Wall St. Rank hold AVIR as of Q3 2024.

  • Colonial Trust Advisors reported no remaining Atea Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Colonial Trust Advisors sold 46 Atea Pharmaceuticals shares in Q3 2024, an estimated $152.
  • Colonial Trust Advisors first reported a position in Atea Pharmaceuticals in Q4 2022 and held it in 7 quarters.
  • Colonial Trust Advisors's Atea Pharmaceuticals position peaked at $221 in Q4 2022.
  • 108 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q3 2024.

Based on Colonial Trust Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.